Top

Journal of the International AIDS Society

Published in:

Open Access 01-12-2010 | Poster presentation

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

Authors: S Spinosa-Guzman, T Van de Casteele, G De La Rosa, P De Doncker

Published in: Journal of the International AIDS Society | Special Issue 4/2010

Excerpt

The open-label, Phase III, ODIN trial randomised treatment-experienced HIV-1-infected patients with no DRV resistance-associated mutations (RAMs) to receive DRV/r 800/100mg qd or DRV/r 600/100mg bid, plus an optimised background regimen (≥2 NRTIs). Non-inferiority in the primary endpoint of virological response at Week 48 was demonstrated with DRV/r qd versus bid dosing: 72.1% vs 70.9% of patients, respectively, achieved HIV-1 RNA <50 copies/mL (95% CI: -6.1, 8.5; p<0.001; ITT-TLOVR). The current analysis explores patient-reported HRQoL. …

Title: Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial
Authors: S Spinosa-Guzman
T Van de Casteele
G De La Rosa
P De Doncker
Publication date: 01-12-2010
Publisher: BioMed Central
Published in: Journal of the International AIDS Society / Issue Special Issue 4/2010
Electronic ISSN: 1758-2652
DOI: https://doi.org/10.1186/1758-2652-13-S4-P26

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Health-related quality of life (HRQoL) assessment with once- and twice-daily darunavir/ritonavir (DRV/r) in the ODIN trial

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 4/2010

Immunological response among patients with undetectable viral load followed for 5 years

Administration of darunavir tablets in patients with difficulties in swallowing – two case reports

Sustained virological response in HIV/HCV co-infected patients without rapid virological response (RVR) on peginterferon-ribavirin therapy

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir

Markers of bone turnover are elevated in patients on antiretrovirals independent of the substance used

High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page